Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer

Jennifer Podolak, Kristi Eilers, Timothy Newby, Rachel Slottke, Erin Tucker, Susan B. Olson, Hui Wen Lue, Jack Youngren, Rahul Aggarwal, Eric J. Small, Julie N. Graff, Joshi J. Alumkal, Tomasz M. Beer, George V. Thomas

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Increased AR activity has been shown to be preserved in spatially distinct metastatic tumors from the same patient suggesting the requirement for lineage-specific dependencies for metastatic castration resistant prostate cancer (mCRPC). Amplification of the AR gene is a common mechanism by which mCRPC increase AR activity. To determine whether AR amplification in circulating tumor cells (CTC) could complement metastatic tissue biopsies in men undergoing treatment for mCRPC, we developed a novel two-step assay to isolate CTCs and subsequently analyzed AR amplification status in CTCs and matched biopsy tissue from the same patient by fluorescence in situ hybridization (FISH). AR gene status in CTCs showed strong concordance with AR gene status in matched tissue samples in 24 of 25 patients (Correlation: 96%; Kappa: 0.83; Sensitivity: 100%, Specificity: 83%). Our work demonstrates that AR amplification is conserved between CTCs and biopsies and that CTCs can serve as non-invasive surrogate to document AR amplification in mCRPC.

Original languageEnglish (US)
Pages (from-to)71447-71455
Number of pages9
JournalOncotarget
Volume8
Issue number42
DOIs
StatePublished - Sep 22 2017

Keywords

  • androgen receptor
  • circulating tumor cells
  • metastases
  • metastatic castration resistant prostate cancer
  • prostate cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer'. Together they form a unique fingerprint.

Cite this